REFERENCES
1. Lippi G, Sanchis-gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5:15.
4. Pastore MC, Vigna M, Saglietto A, et al. Prognostic value of left atrial strain in acute and chronic heart failure: a meta-analysis. ESC Heart Fail. 2025;12:2921-31.
5. Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70:2476-86.
6. Vilella-Figuerola A, Gallinat A, Escate R, Mirabet S, Padró T, Badimon L. Systems biology in chronic heart failure-identification of potential miRNA regulators. Int J Mol Sci. 2022;23.
7. Gheorghiade M, Zannad F, Sopko G, et al. ; International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation. 2005;112:3958-68.
8. Deniau B, Costanzo MR, Sliwa K, Asakage A, Mullens W, Mebazaa A. Acute heart failure: current pharmacological treatment and perspectives. Eur Heart J. 2023;44:4634-49.
9. Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. Nat Rev Mol Cell Biol. 2019;20:5-20.
11. Ozata DM, Gainetdinov I, Zoch A, O'Carroll D, Zamore PD. PIWI-interacting RNAs: small RNAs with big functions. Nat Rev Genet. 2019;20:89-108.
12. Aravin AA, Sachidanandam R, Bourc'his D, et al. A piRNA pathway primed by individual transposons is linked to de novo DNA methylation in mice. Mol Cell. 2008;31:785-99.
13. Gu X, Zhang Y, Qin X, Ma S, Huang Y, Ju S. Transfer RNA-derived small RNA: an emerging small non-coding RNA with key roles in cancer. Exp Hematol Oncol. 2022;11:35.
14. Schaefer M, Pollex T, Hanna K, et al. RNA methylation by Dnmt2 protects transfer RNAs against stress-induced cleavage. Genes Dev. 2010;24:1590-5.
15. Zhao L, Peng Y, Su P. Expression profiles and functional analysis of tRNA-derived small RNAs in epicardial adipose tissue of patients with heart failure. Ann Med. 2023;55:2267981.
16. Su Z, Wilson B, Kumar P, Dutta A. Noncanonical roles of tRNAs: tRNA fragments and beyond. Annu Rev Genet. 2020;54:47-69.
17. Cao J, Cowan DB, Wang DZ. tRNA-derived small RNAs and their potential roles in cardiac hypertrophy. Front Pharmacol. 2020;11:572941.
18. Zhang L, Liu J, Hou Y. Classification, function, and advances in tsRNA in non-neoplastic diseases. Cell Death Dis. 2023;14:748.
19. Kiss T. Small nucleolar RNA-guided post-transcriptional modification of cellular RNAs. EMBO J. 2001;20:3617-22.
20. Kishore S, Stamm S. Regulation of alternative splicing by snoRNAs. Cold Spring Harbor Symp Quant Biol. 2006;71:329-34.
21. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e263-421.
22. Mann DL, Felker GM. Mechanisms and models in heart failure: a translational approach. Circ Res. 2021;128:1435-50.
23. Du B, Fu Q, Yang Q, et al. Different types of cell death and their interactions in myocardial ischemia-reperfusion injury. Cell Death Discov. 2025;11:87.
24. McDonagh TA, Metra M, Adamo M, et al. ; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599-726.
25. Yang J, Xue FT, Li YY, Liu W, Zhang S. Exosomal piRNA sequencing reveals differences between heart failure and healthy patients. Eur Rev Med Pharmacol Sci. 2018;22:7952-61.
26. Zhong N, Nong X, Diao J, Yang G. piRNA-6426 increases DNMT3B-mediated SOAT1 methylation and improves heart failure. Aging. 2022;14:2678-94.
27. Wang K, Zhou LY, Liu F, et al. PIWI-interacting RNA HAAPIR regulates cardiomyocyte death after myocardial infarction by promoting NAT10-mediated ac4C acetylation of Tfec mRNA. Adv Sci. 2022;9:e2106058.
28. Wang K, Li FH, Zhou LY, et al. HNEAP regulates necroptosis of cardiomyocytes by suppressing the m5C Methylation of Atf7 mRNA. Adv Sci. 2023;10:e2304329.
29. Huang Y, Li Y, Zhang K, et al. Expression and diagnostic value of PIWI-interacting RNA by serum in acute myocardial infarction. J Cardiol. 2023;82:441-7.
30. Law PT, Qin H, Ching AK, et al. Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma. J Hepatol. 2013;58:1165-73.
31. Guo J, Chen X, Ren J, Wang Y, Wang K, Yang S. The role of tRNA-derived small RNAs (tsRNAs) in regulating cell death of cardiovascular diseases. Biology. 2025;14:218.
32. Wang C, Gao Y, Liu K, et al. tiRNA-HAR contributes to ischemic myocardial injury via facilitating HuR-mediated stability of p53. Transl Res. 2025;280:17-28.
33. Tao EW, Wang HL, Cheng WY, Liu QQ, Chen YX, Gao QY. A specific tRNA half, 5’tiRNA-His-GTG, responds to hypoxia via the HIF1α/ANG axis and promotes colorectal cancer progression by regulating LATS2. J Exp Clin Cancer Res. 2021;40:67.
34. Deng L, Weng Y, Lin J, et al. A tRNA-derived fragment tiRNA-Met-CAT-002 induced by myocardial ischemia/reperfusion injury inhibits cardiomyocyte autophagy by regulating Bnip3. Exp Cell Res. 2025;453:114809.
35. Santovito D, Steffens S, Barachini S, Madonna R. Autophagy, innate immunity, and cardiac disease. Front Cell Dev Biol. 2023;11:1149409.
36. Su J, Cheng J, Hu Y, et al. Transfer RNA-derived small RNAs and their potential roles in the therapeutic heterogeneity of sacubitril/valsartan in heart failure patients after acute myocardial infarction. Front Cardiovasc Med. 2022;9:961700.
37. Greene SJ, Fonarow GC, DeVore AD, et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73:2365-83.
38. Goossens EAC, Zhang L, de Vries MR, Jukema JW, Quax PHA, Nossent AY. Cold-inducible RNA-binding protein but not its antisense lncRNA is a direct negative regulator of angiogenesis in vitro and in vivo via regulation of the 14q32 angiomiRs-microRNA-329-3p and microRNA-495-3p. Int J Mol Sci. 2021;22:12678.
39. Håkansson KEJ, Goossens EAC, Trompet S, et al. Genetic associations and regulation of expression indicate an independent role for 14q32 snoRNAs in human cardiovascular disease. Cardiovasc Res. 2019;115:1519-32.
40. van Ingen E, Engbers PAM, Woudenberg T, et al. C/D box snoRNA SNORD113-6 guides 2’-O-methylation and protects against site-specific fragmentation of tRNA(Leu)(TAA) in vascular remodeling. Mol Ther Nucleic Acids. 2022;30:162-72.
41. Chabronova A, Holmes TL, Hoang DM, et al. SnoRNAs in cardiovascular development, function, and disease. Trends Mol Med. 2024;30:562-78.
42. Ni Y, Deng J, Bai H, Liu C, Liu X, Wang X. CaMKII inhibitor KN-93 impaired angiogenesis and aggravated cardiac remodelling and heart failure via inhibiting NOX2/mtROS/p-VEGFR2 and STAT3 pathways. J Cell Mol Med. 2022;26:312-25.
43. Li Y, Ruan X, Xu X, et al. Shengmai injection suppresses angiotensin II-induced cardiomyocyte hypertrophy and apoptosis via activation of the AMPK signaling pathway through energy-dependent mechanisms. Front Pharmacol. 2019;10:1095.
44. Gao XQ, Zhang YH, Liu F, et al. The piRNA CHAPIR regulates cardiac hypertrophy by controlling METTL3-dependent N6-methyladenosine methylation of Parp10 mRNA. Nat Cell Biol. 2020;22:1319-31.
45. Alcaide P, Kallikourdis M, Emig R, Prabhu SD. Myocardial Inflammation in Heart Failure With Reduced and Preserved Ejection Fraction. Circ Res. 2024;134:1752-66.
46. Wu X, Wang R, Chen X, Wang K. Advances in RNA modification in myocardial fibrosis (Review). Int J Mol Med. 2025;56:218.
47. Kuba K, Zhang L, Imai Y, et al. Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res. 2007;101:e32-42.
48. Chen B, Shi B, Zhou Z, et al. Targeting a cardiac abundant and fibroblasts-specific piRNA (CFRPi) to attenuate and reverse cardiac fibrosis in pressure-overloaded heart failure. Transl Res. 2024;267:10-24.
49. Lv L, Yuan K, Li J, et al. PiRNA CFAPIR inhibits cardiac fibrosis by regulating the muscleblind-like protein MBNL2. Biochim Biophys Acta Mol Basis Dis. 2024;1870:167456.
50. Li W, Lan M, Xu K, et al. Screening and evaluation of tRF-Glu-CTC-013 as a biomarker and key regulator in the development of cardiac hypertrophy. Int J Med Sci. 2025;22:2839-51.
51. Jung P, Seibertz F, Fakuade FE, et al. Increased cytosolic calcium buffering contributes to a cellular arrhythmogenic substrate in iPSC-cardiomyocytes from patients with dilated cardiomyopathy. Basic Res Cardiol. 2022;117:5.
52. Hutchings DC, Madders GWP, Niort BC, et al. Interaction of background Ca2+ influx, sarcoplasmic reticulum threshold and heart failure in determining propensity for Ca2+ waves in sheep heart. J Physiol. 2022;600:2637-50.
53. Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res. 2013;113:709-24.
54. Lemaitre RN, Jensen PN, Hoofnagle A, et al. Plasma ceramides and sphingomyelins in relation to heart failure risk. Circ Heart Fail. 2019;12:e005708.
55. Yu J, Pan W, Shi R, et al. Ceramide is upregulated and associated with mortality in patients with chronic heart failure. Can J Cardiol. 2015;31:357-63.
56. Sasset L, Manzo OL, Zhang Y, et al. Nogo-a reduces ceramide de novo biosynthesis to protect from heart failure. Cardiovasc Res. 2023;119:506-19.
57. RETRACTION: α-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 2024;38:e70007. [PMID: 39177105].
58. Santulli G, Iaccarino G. Adrenergic signaling in heart failure and cardiovascular aging. Maturitas. 2016;93:65-72.
59. Lin LY, Wu CK, Juang JM, et al. Myocardial regional interstitial fibrosis is associated with left intra-ventricular dyssynchrony in patients with heart failure: a cardiovascular magnetic resonance study. Sci Rep. 2016;6:20711.
60. Trial J, Entman ML, Cieslik KA. Mesenchymal stem cell-derived inflammatory fibroblasts mediate interstitial fibrosis in the aging heart. J Mol Cell Cardiol. 2016;91:28-34.
61. Shen L, Gan M, Tan Z, et al. A novel class of tRNA-derived small non-coding RNAs respond to myocardial hypertrophy and contribute to intergenerational inheritance. Biomolecules. 2018;8:54.
62. Zhao Y, Wang R, Qin Q, Yu J, Che H, Wang L. Differentially expressed tRNA-derived fragments and their roles in primary cardiomyocytes stimulated by high glucose. Front Endocrinol. 2022;13:1049251.
63. Schena GJ, Murray EK, Hildebrand AN, et al. Cortical bone stem cell-derived exosomes’ therapeutic effect on myocardial ischemia-reperfusion and cardiac remodeling. Am J Physiol Heart Circ Physiol. 2021;321:H1014-29.
64. Elliott BA, Ho HT, Ranganathan SV, et al. Modification of messenger RNA by 2’-O-methylation regulates gene expression in vivo. Nat Commun. 2019;10:3401.
65. Sun X, Wang G, Luo W, et al. Small but strong: the emerging role of small nucleolar RNA in cardiovascular diseases. Front Cell Dev Biol. 2023;11:1292925.
66. Shivam P, Ball D, Cooley A, et al. Regulatory roles of PIWI-interacting RNAs in cardiovascular disease. Am J Physiol Heart Circ Physiol. 2025;328:H991-H1004.
67. Cheang I, Zhu Q, Liao S, Li X. Current understanding of piRNA in cardiovascular diseases. Front Mol Med. 2021;1:791931.
68. Das S, Shah R, Dimmeler S, et al. ; American Heart Association Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Noncoding RNAs in cardiovascular disease: current knowledge, tools and technologies for investigation, and future directions: a scientific statement from the American Heart Association. Circ Genom Precis Med. 2020;13:e000062.
69. Gainetdinov I, Colpan C, Cecchini K, et al. Terminal modification, sequence, length, and PIWI-protein identity determine piRNA stability. Mol Cell. 2021;81:4826-4842.e8.
70. Cecchini K, Ajaykumar N, Bagci A, Zamore PD, Gainetdinov I. Mouse pachytene piRNAs cleave hundreds of transcripts, but alter the steady-state abundance of only a minority of targets. bioRxiv. 2024.
71. Czech B, Hannon GJ. One loop to rule them all: the ping-pong cycle and piRNA-guided silencing. Trends Biochem Sci. 2016;41:324-37.
72. Qin HL, Han Y, Li JQ, et al. piRNA28846 has the potential to be a novel RNA nucleic acid drug for ovarian cancer. NPJ Precis Oncol. 2025;9:65.
73. Bereczki Z, Benczik B, Balogh OM, et al. Mitigating off-target effects of small RNAs: conventional approaches, network theory and artificial intelligence. Br J Pharmacol. 2025;182:340-79.
74. Bartoszewski R, Sikorski AF. Editorial focus: understanding off-target effects as the key to successful RNAi therapy. Cell Mol Biol Lett. 2019;24:69.
75. Czech B, Munafò M, Ciabrelli F, et al. piRNA-guided genome defense: from biogenesis to silencing. Annu Rev Genet. 2018;52:131-57.
76. Perera BPU, Wang K, Wang D, et al. Sex and tissue-specificity of piRNA regulation in adult mice following perinatal lead (Pb) exposure. Epigenetics. 2024;19:2426952.
77. Li Y, Bhinge A, Inoue S, Garcia G. Editorial: Noncoding RNAs in neurodegenerative disorders: from current insights and future directions to translational modeling and therapeutic approaches. Front Neurosci. 2024;18:1497673.
